Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US-2017362573-A1 · Dec 21, 2017 · US
US2019100731A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019100731-A1 |
| Application number | US-201716085623-A |
| Country | US |
| Kind code | A1 |
| Filing date | Mar 17, 2017 |
| Priority date | Mar 17, 2016 |
| Publication date | Apr 4, 2019 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A method of preparing an ex-vivo intestinal culture model is provided. The method comprising: (a) providing an intestinal tissue sample; (b) treating the intestinal tissue sample with a protease cleaving an extracellular matrix (ECM) component so as to break cell-cell contacts and obtain an intestinal preparation which maintains the overall intestinal tissue structure including villi and/or intestinal tissue layer orientation; (c) washing the preparation; and (d) culturing the preparation.
Opening claim text (preview).
1 . A method of preparing an ex-vivo intestinal culture model, the method comprising: (a) providing an intestinal tissue sample; (b) treating said intestinal tissue sample with a protease cleaving an extracellular matrix (ECM) component so as to break cell-cell contacts and obtain an intestinal preparation which maintains the overall intestinal tissue structure including villi and/or intestinal tissue layer orientation; (c) washing said preparation; and (d) culturing said preparation. 2 . (canceled). 3 . The method of claim 1 , wherein said protease comprises a protease combination comprising collagenase and dispase. 4 . The method of claim 3 , wherein said collagenase is collagenase 1A. 5 . The method of claim 3 , wherein a concentration of dispase comprises 0.05 U/ml to about 0.15 U/ml units per 3 mm 3 of the tissue. 6 . The method of claim 3 , wherein a concentration of collagenase comprises 0.1 mg/ml to about 1.0 mg/ml per 3 mm 3 of the tissue. 7 . The method of claim 1 , wherein said washing is repeated at least 2-3 times. 8 . The method of claim 1 , wherein said intestinal tissue sample is pathologic. 9 . The method of claim 7 , wherein said intestinal tissue sample comprises an inflamed tissue. 10 - 15 . (canceled) 16 . The method of claim 1 , wherein said culturing said preparation comprises placing said preparation in a culture vessel with villus surface facing up. 17 . The method of claim 1 , wherein said culturing said preparation comprises placing said preparation on a tissue culture insert. 18 . The method of claim 1 , wherein said culturing is for at least 2-4 days. 19 . An ex-vivo intestinal culture model obtainable according to the method of claim 1 . 20 . A method for screening a candidate agent for an effect on a mammalian tissue, the method comprising: (a) contacting a candidate agent with the intestinal culture model of claim 19 , and (b) determining the effect of the agent on the intestinal culture model. 21 . A method of selecting a drug for the treatment of an intestinal disease in a subject in need thereof, the method comprising: (a) contacting the drug with the intestinal culture model of claim 19 of the subject; and (b) determining the effect of said drug on the intestinal culture model, wherein sensitivity of said intestinal culture model to said drug indicates efficacy of said drug for the treatment of said intestinal disease. 22 . A method of treating an intestinal disease in a subject in need thereof, the method comprising: (a) selecting a drug according to the method of claim 21 ; and (b) administering to said subject a therapeutically effective amount of a drug demonstrating efficacy for the treatment of said disease in said subject, thereby treating the disease in the subject. 23 . The method of claim 20 , further comprising stimulating an inflammatory response in said the intestinal culture model prior to or concomitantly with said contacting. 24 . The method of claim 20 , wherein said drug or agent is a drug or agent combination. 25 . The method of claim 20 , wherein said drug comprises a cannabinoid. 26 - 28 . (canceled) 29 . The method of claim 20 , wherein said determining said effect is by determining a secreted molecule. 30 . (canceled)
Cells of the gastro-intestinal tract · CPC title
for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title
Methods for the dissociation of cells, e.g. specific use of enzymes · CPC title
from plants · CPC title
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q) · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.